When to Start Hormone Therapy: New Research on Perimenopause Timing
A lot of women come to me after years of waiting.
They waited because they thought their symptoms weren’t bad enough.
They waited because their doctor told them to come back when things got worse.
They waited because they weren’t sure hormone therapy was right for them, or because they were still hoping things would settle down on their own.
By the time they decide to have a real conversation about HRT, they’ve often been dealing with sleep disruption, mood changes, weight gain, and low energy for three, five, even ten years.
New research suggests that waiting may come at a cost.
What the Research Found
At the 2025 Annual Meeting of The Menopause Society, researchers presented findings from one of the largest analyses to date on hormone therapy timing. The study used a retrospective cohort analysis based on data from more than 120 million patient records.
The question was simple. Does it matter when a woman starts hormone therapy?
The researchers compared three groups:
- Women who started estrogen therapy during perimenopause, within ten years prior to menopause
- Women who started after menopause
- Women who never used hormone therapy at all
They looked at rates of breast cancer, heart attack, and stroke across all three groups.
The results were notable. Women who started estrogen during perimenopause showed no significantly higher rates of breast cancer, heart attack, or stroke compared to the other groups. In other words, the fears that have kept women away from HRT for two decades were not borne out in the perimenopausal starters.
What the researchers highlighted instead was the potential benefit of earlier initiation for long-term health outcomes.
Why Timing Seems to Matter
The idea that when you start HRT matters isn’t new, but the evidence keeps getting stronger.
Researchers refer to this as the “timing hypothesis.” The basic idea is that estrogen has protective effects on the cardiovascular system, bones, and brain, and those effects are most beneficial when hormone levels are maintained during the transition rather than restored after years of deficiency.
During perimenopause, your body is already adjusting to declining and fluctuating estrogen. Blood vessels, bone tissue, and neural pathways are all responding to hormonal changes in real time. When hormone therapy is introduced during this period, it supports systems that are still flexible and responsive.
When HRT is started many years after menopause, the picture shifts. Blood vessels may already have atherosclerotic changes. Bone loss may already be significant. The therapy still has benefits, but the protective effects are generally smaller.
This is why The Menopause Society and other major organizations have increasingly recommended considering hormone therapy during perimenopause or within ten years of menopause for women who are good candidates.
Rethinking “Bad Enough”
One of the most common reasons women wait is the belief that their symptoms aren’t severe enough to warrant treatment.
Hot flashes haven’t started yet. Periods are still somewhat regular. Sleep is disrupted but manageable. Mood changes come and go. The logic is understandable. Why intervene if things aren’t really that bad?
The research suggests that this framing may be backwards. The women who tend to benefit most from hormone therapy often start it before symptoms become debilitating, when the hormonal shifts are beginning but the downstream effects on the body are still reversible.
Waiting until symptoms are severe may feel like the responsible choice. In practice, it can mean missing the period when the treatment offers the greatest long-term benefit.
What This Doesn’t Mean
A few important clarifications.
This research doesn’t mean every woman in perimenopause should be on hormone therapy. The decision is still individual. It depends on your symptoms, your medical history, your risk profile, and your preferences.
It also doesn’t mean that women past menopause can’t benefit from HRT. Many still can. The data simply suggests that the risk-benefit calculation is most favorable earlier in the transition.
And it doesn’t mean you’ve missed your chance if you haven’t started yet. Decisions about hormone therapy are made in the present, with the information available now, based on where you are today.
The point of this research is not to create urgency or regret. It’s to give women better information than they’ve had, so they can make decisions based on updated science rather than on assumptions from twenty years ago.
The Practical Takeaway
If you’re in your late 30s or 40s and noticing changes you suspect are hormonal, the conversation is worth having now rather than later.
Not because you need to act immediately. Not because hormone therapy is the right answer for every woman. But because the decision is an informed one either way, and the current research is pointing clearly toward earlier engagement being better than delayed.
A consultation doesn’t commit you to treatment. It gives you a complete picture of where your hormones are, what your options look like, and what the realistic timeline would be if you decided to move forward.
For the women I work with, that conversation often turns out to be the thing they wish they’d had years earlier.
